Combining neoadjuvant TMZ (75 mg/m2/day for 14 days) treatment followed by autologous tumor lysate-loaded DC therapy with consecutive IL-2 (3 mIU/day for 5 days) in 17 melanoma patients, also significantly depleted Tregs, although this did not correlate to clinical outcome. Here, IL2 is linked to neoplasm.